HCWB · HCW Biologics Inc. · Executive Compensation
$1.57
-0.07 (-4.27%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Company's condensed financial statements, without additional funding or financial support. After considering management's plan for financing and funds raised that are probable to occur within one year, as well as that the Company expects to continue to incur losses from operations for the foreseeable future, management concluded that the substantial doubt that existed in its going concern analysis as of June 30, 2026 was not alleviated.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.54M
Shares
1.84M
Volume · Oct 6
37.83K
Avg daily vol (3M)
371.87K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | Chief Executive Officer | $438,656 |
| Rebecca Byam | Chief Financial Officer | $309,309 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $263,895 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | Chief Executive Officer | $368,188 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $261,667 |
| Rebecca Byam | Chief Financial Officer | $154,236 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | Chief Executive Officer | $425,880 |
| Rebecca Byam | Chief Financial Officer | $330,300 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $251,160 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | Chief Executive Officer | $421,050 |
| Rebecca Byam | Chief Financial Officer | $297,080 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $248,570 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Hing C. Wong | Chief Executive Officer | $2,972,838 |
| Rebecca Byam | Chief Financial Officer | $982,140 |
| Peter Rhode | Chief Scientific Officer and Vice President of Clinical Operations | $297,769 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gary M. Winer | Board of Directors | Resigned | 2025-06-23 |